Parameters | Univarite analysis | Multivarite analysis | ||||
---|---|---|---|---|---|---|
Hazard ratio | 95% CI | p value | Hazard ratio | 95% CI | p value | |
Age at operation (years old) | ||||||
 ≤ 60 versus > 60 | 0.871 | 0.040–9.101 | 0.910 |  |  |  |
Tumor size (mm) | ||||||
 ≤ 20.0 versus > 20.0 | 1.798 | 0.172–38.728 | 0.623 |  |  |  |
Tumor size (mm) | ||||||
 ≤ 30.0 versus > 30.0 | – | – | 0.265 |  |  |  |
Pathological lymph node metastasis | ||||||
pN0, pN1mi versus pN1a | 21.520 | 1.878–488.577 | 0.016 | 17.339 | 1.112–530.855 | 0.042 |
Progesterone receptor | ||||||
Negative versus positive | – | – | 0.545 |  |  |  |
Ki67 | ||||||
 ≤ 20% versus > 20% | 1.806 | 0.084–18.864 | 0.642 |  |  |  |
Surgical treatment | ||||||
BCT and radiation therapy versus mastectomy | 0.422 | 0.020–4.410 | 0.467 |  |  |  |
Lymphatic invasion | ||||||
ly0 versus ly1 | 1.906 | 0.182–41.094 | 0.589 |  |  |  |
Venous invasion | ||||||
v0 versus v1 | 3.760 | 0.174–39.725 | 0.327 |  |  |  |
Nuclear grade | ||||||
1, 2 versus 3 | – | – | 0.294 |  |  |  |
Adjuvant endocrine therapy | ||||||
TAM (+ LH-RH agonist) versus ANA | 0.422 | 0.020–4.410 | 0.467 |  |  |  |
Disease free survival (days) | ||||||
 ≤ 1462 versus > 1462 | 1.229 | 0.056–13.152 | 0.870 |  |  |  |
Primary recurrence site | ||||||
Locoregional recurrence versus Distant metastasis | 9.331 | 0.877–202.892 | 0.063 | 6.057 | 0.414–178.741 | 0.187 |
TILs density | ||||||
 ≤ 10 versus > 10 | 3.405 | 0.158–35.582 | 0.360 |  |  |  |
TILs | ||||||
Absent versus Not absent | 0.211 | 0.018–4.800 | 0.269 |  |  |  |